Skip to main content
SpringerLink
Log in

The public is being warned by the US FDA about a potential risk associated with opioid analgesic

  • News item
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. US FDA.Endo Pharmaceuticals Opiate Products by Novartis Consumer Health: Public Health Advisory - Potential Safety Risk. FDA Drug Safety Newsletter: [1 page], 9 Jan 2012. Available from: URL: http://www.fda.gov

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

The public is being warned by the US FDA about a potential risk associated with opioid analgesic. React. Wkly. 1384, 4 (2012). https://doi.org/10.2165/00128415-201213840-00012

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128415-201213840-00012

Keywords

Search

Navigation